Status:
COMPLETED
Two Different Collection Sets for Peripheral Blood Progenitor Cell Apheresis With Spectra Optia®
Lead Sponsor:
Heinrich-Heine University, Duesseldorf
Collaborating Sponsors:
Terumo BCT
Chugai Pharma USA
Conditions:
Healthy Allogeneic Donors
Granulocyte Colony-stimulating Factor (G-CSF) Mobilized
Eligibility:
All Genders
18-60 years
Phase:
NA
Brief Summary
The study will determine the advantage of the Spectra Optia® IDL set compared to the standard collection set for collection of peripheral blood progenitor cells using the Spectra Optia® apheresis syst...
Detailed Description
Peripheral blood progenitor cells (PBPC) collected by apheresis are the most common stem cell source for allogeneic hematopoietic stem cell transplantation. Recently, Terumo BCT introduced a novel au...
Eligibility Criteria
Inclusion
- ability to give informed consent to participate in the study
- meets german eligibility criteria (ZKRD-Standards, hemotherapy guidelines) for peripheral blood stem cell donation
- has been treated with G-CSF 10 µg per kg per day for 5 days
Exclusion
- demand of concurrent plasma
Key Trial Info
Start Date :
March 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2014
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT01901458
Start Date
March 1 2014
End Date
November 1 2014
Last Update
March 19 2015
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Cellex GmbH / Zentrum für Zellgewinnung (Standort Köln)
Cologne, Germany, 50670
2
Institut für Transplantantionsdiagnostik und Zelltherapeutika
Düsseldorf, Germany, 40225